An investigation on behalf of investors of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares over potential securities laws violations by Sonoma Pharmaceuticals, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) concerning whether a series of statements by Sonoma Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Woodstock, GA based Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally.

On November 17, 2020, Sonoma Pharmaceuticals, Inc. filed a Form with the U.S. Securities and Exchange Commission announcing that Sonoma Pharmaceuticals unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon. Sonoma continued that the financial statements for this time period contained material errors and that the Company will need to restate them.

Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) declined from $8.05 per share on November 16, 2020 to as low as $6.52 per share on November 18, 2020.